|
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
|
02 October 2025 |
|
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
|
10 September 2025 |
|
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
|
04 September 2025 |
|
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
|
30 April 2025 |
|
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
|
08 August 2024 |
|
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
|
07 May 2024 |
|
Novartis presents new data on safety and efficacy of Zolgensma
|
04 March 2024 |
|
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
|
21 September 2023 |
|
Novartis completes acquisition of Chinook Therapeutics
|
28 August 2023 |
|
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
|
19 July 2023 |